Inflammatory myopathies: Disease mechanisms

Current Opinion in Neurology

Volumn 22, Issue 5, 2009, Pages 516-523

  Greenberg, Steven A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Dermatomyositis; Inclusion body myositis; Inflammatory myopathies

Indexed keywords

BETA SECRETASE; INTERFERON; TAR DNA BINDING PROTEIN;

DERMATOMYOSITIS; GENOMICS; HUMAN; INCLUSION BODY MYOSITIS; MUSCLE ATROPHY; MUSCLE FUNCTION; MYOSITIS; NONHUMAN; PATHOGENESIS; PROTEOMICS; REVIEW;

AMYLOID; ATROPHY; DERMATOMYOSITIS; DNA-BINDING PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON TYPE I; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY;

EID: 70349676026     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283311ddf     Document Type: Review

References (52)

1. Waschbisch A, Wintterle S, Lochmuller H, et al. Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. Arthritis Rheum 2008; 58:3600-3608.
2. Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and HLA-class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK adult-onset Caucasian myositis. Ann Rheum Dis 2008 [Epub ahead of print].
3. Suber TL, Casciola-Rosen L, Rosen A. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 2008; 4:201-209.
4. Hollemann D, Budka H, Loscher WN, et al. Endothelial and myogenic differentiation of hematopoietic progenitor cells in inflammatory myopathies. J Neuropathol Exp Neurol 2008; 67:711-719.
5. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69:2008-2019.
6. Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007; 56:3784-3792.
7. A phase 1B, randomized, double-blind, placebo-controlled, multicenter study to evaluate safety of multiple-dose, intravenously administered MEDI-545, a fully human anti interferon-alpha monoclonal antibody, in adult patients with dermatomyositis or polymyositis. http://clinicaltrialsgov/ct2/ show/NCT00533091.
8. Norton WL, Velayos E, Robison L. Endothelial inclusions in dermatomyositis. Ann Rheum Dis 1970; 29:67-72.
9. Banker BQ. Dermatomyostis of childhood, ultrastructural alteratious of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol 1975; 34:46-75.
10. Carpenter S, Karpati G, Rothman S, Watters G. The childhood type of dermatomyositis. Neurology 1976; 26:952-962.
11. De Visser M, Emslie-Smith AM, Engel AG. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989; 94:181-192.
12. Grimley PM, Davis GL, Kang YH, et al. Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon. Lab Invest 1985; 52:638-649.
13. Marquart KH, Engst R, Oehlschlaegel G. Human recombinant leukocyte interferon-alpha induces intracytoplasmic tubuloreticular structures and crystalline bodies in Kaposi's sarcoma cells in vivo. Arch Dermatol Res 1990; 282:371-373.
14. Schaff Z, Hoofnagle JH, Grimley PM. Hepatic inclusions during interferon therapy in chronic viral hepatitis. Hepatology 1986; 6:966-970.
15. Feldman D, Goldstein AL, Cox DC, Grimley PM. Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 20,50 oligoadenylate synthetase induction. Lab Invest 1988; 58:584-589.
16. Rich SA.Human lupusinclusions and interferon.Science1981;213:772-775.
17. Rich SA, Owens TR, Bartholomew LE, Gutterman JU. Immune interferon does not stimulate formation of alpha and beta interferon induced human lupus-type inclusions. Lancet 1983; 1:127-128.
18. Kuyama J, Kanayama Y, Mizutani H, et al. Formation of tubuloreticular inclusions in mitogen-stimulated human lymphocyte cultures by endogenous or exogenous alpha-interferon. Ultrastruct Pathol 1986; 10:77-85.
19. Greenberg SA, Amato AA. Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol 2004; 17:359-364.
20. Bronner IM, Hoogendijk JE, Veldman H, et al. Tubuloreticular structures in different types of myositis: implications for pathogenesis. Ultrastruct Pathol 2008; 32:123-126.
21. Greenberg SA, Fiorentino D. Similar topology of injury to keratinocytes and myofibres in dermatomyositis skin and muscle. Br J Dermatol 2009; 160: 464-465.
22. Chou SM. Myxovirus-like structures in a case of human chronic polymyositis. Science 1967; 158:1453-1455.
23. Chou SM. Myxovirus-like structures and accompanying nuclear changes in chronic polymyositis. Arch Pathol 1968; 86:649-658.
24. Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978; 28:8-17.
25. Karpati G, Carpenter S. Pathology of the inflammatory myopathies. Baillieres Clin Neurol 1993; 2:527-556.
26. Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of a singlestranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994; 144:874-882.
27. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705-713.
28. Carpenter S. Inclusion body myositis, a review. J Neuropathol Exp Neurol 1996; 55:1105-1114.
29. Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006; 34:406-416.
30. Nakano S, Shinde A, Fujita K, et al. Histone H1 is released from myonuclei and present in rimmed vacuoles with DNA in inclusion body myositis. Neuromuscul Disord 2008; 18:27-33.
31. Greenberg SA, Watts GD, Kimonis VE, et al. Nuclear localization of valosincontaining protein in normal muscle and muscle affected by inclusion-body myositis. Muscle Nerve 2007; 36:447-454.
32. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008; 79:1186-1189.
33. Olive M, Janue A, Moreno D, et al. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009; 68:262-273.
34. Salajegheh M, Pinkus JL, Amato AA, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40:19-31.
35. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314:130-133.
36. Kwong LK, Uryu K, Trojanowski JQ, Lee VM. TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 2008; 16:41-51.
37. Mezei MM, Mankodi A, Brais B, et al. Minimal expansion of the GCG repeat in the PABP2 gene does not predispose to sporadic inclusion body myositis. Neurology 1999; 52:669-670.
38. Ayala YM, Misteli T, Baralle FE. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A 2008; 105:3785-3789. This study reports that in cell culture studies, depletion of TDP-43 by siRNA
39. Li J, Yin C, Okamoto H, et al. Proteomic analysis of inclusion body myositis. J Neuropathol Exp Neurol 2006; 65:826-833.
40. Hutchinson DO, Jongbloed B. Two-dimensional gel electrophoresis in inclusion body myositis. J Clin Neurosci 2008; 15:440-444.
41. Parker KC, Kong SW, Walsh RJ, et al. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve 2009 [Epub ahead of print].
42. De Bleecker JL, Engel AG, Butcher EC. Peripheral lymphoid tissue-like adhesion molecule expression in nodular infiltrates in inflammatory myopathies. Neuromuscul Disord 1996; 6:255-260.
43. Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59:1170-1182.
44. Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005; 65:1782-1787.
45. Bradshaw EM, Orihuela A, McArdel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007; 178: 547-556.
46. Lopez De Padilla CM, Vallejo AN, Lacomis D, et al. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009; 60:1160-1172.
47. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007; 35:17-23.
48. Tateyama M, Fujihara K, Misu T, Itoyama Y. CCR7+ myeloid dendritic cells together with CCR7+ T cells and CCR7+ macrophages invade CCL19+ nonnecrotic muscle fibers in inclusion body myositis. J Neurol Sci 2009; 279:47-52.
49. Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics 2008; 5:548-557.
50. Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. Br Med J 2009; 339:b2680.
51. Greenberg SA. Comment on 'Interrelation of inflammation and APP in sIBM: IL-1beta induces accumulation of beta-amyloid in skeletal muscle'. Brain 2009; 132:e106.
52. Schmidt J, Dalakas MC. Inflammation interrelates to APP in sIBM: IL-1beta induces accumulation of beta-amyloid. Brain 2009; 132:e107.